Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion

Nuclear Medicine Communications

Volumn 29, Issue 6, 2008, Pages 568-573

  Kanetaka, Hidekazu ^a   Hanyu, Haruo ^a   Hirao, Kentaro ^a   Shimizu, Soichiro ^a   Sato, Tomohiko ^a   Akai, Tomotaka ^a   Iwamoto, Toshihiko ^a   Koizumi, Kiyoshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Donepezil; Frontal lobe; Response; Substantia innominata

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ANTERIOR COMMISSURE; ARTICLE; BRAIN ATROPHY; BRAIN PERFUSION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC PROCEDURE; SUBSTANTIA INNOMINATA; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; BRAIN; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; INDANS; MALE; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANTIA INNOMINATA; SUBTRACTION TECHNIQUE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 43149090757     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f5e5f4     Document Type: Article

References (29)

1. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of Aricept in patients with Alzheimer's disease. Neurology 1998; 50:136-145.
2. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord 2000; 14(suppl):S3-S10.
3. Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. Neurosci Lett 2002; 319:33-36.
4. Riekkinen Jr P, Riekkinen M, Soininen H, Kuikka J, Laakso M, Riekkinen Sr P. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport 1997; 8:1845-1849.
5. Hanyu H, Shimizu T, Tanaka Y, Takasaki M, Koizumi K, Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15:177-182.
6. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993; 110:395-401.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944.
8. Folstein MF, Folstein SE, McHugh PR. ‘Mini Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
9. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.
10. Sands LP, Kats I, Schneider L. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 1999; 13:26-33.
11. Sasaki M, Ehara S, Tamakawa Y, Takahashi S, Tohgi H, Sakai A, et al. MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary study. AJNR Am J Neuroradiol 1995; 16:2001-2007.
12. Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol 2002; 23:27-32.
13. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238-1248.
14. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994; 35:1528-1537.
15. Talairach J, Tournoux P. Co-planar Stereotactic Atlas of the Human Brain. New York: Thieme; 1988.
16. Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003; 17:289-295.
17. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994; 343:176.
18. Wilcock GK, Scott MI. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 1994; 344:544.
19. Querfurth HW, Allam GL, Geffroy MA, Schiff HB, Kaplan RF. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot study. Dement Geriatr Cogn Disord 2000; 11:314-321.
20. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15:794-802.
21. Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease, clinical and pathological findings. Br J Psychiatry 1993; 162:385-392.
22. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43:1927-1934.
23. Perry E, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5:747-749.
24. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54:407-411.
25. Liberini P, Valerio A, Memo M, Spano P. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? Trends Pharmacol Sci 1996; 17:155-160.
26. Muir JL, Everitt BJ, Robbins TW. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansertron. Psychopharmacology 1995; 118:82-92.
27. Vidal C. Nicotinic potentiation of glutaminergic synapses in the prefrontal cortex: new insight into the analysis of the role of nicotinic receptors in cognitive functions. Drug Dev Res 1994; 31:120-126.
28. Riekkinen P, Soininen H, Helkala E-L, Partanen K, Laasko M, Vanhanen M, et al. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport 1995; 6:1297-1300.
29. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997; 350:232-233.